Professor Zhang Tongcuun

Professor Zhang Tongcuun

Position: Founder and CEO
Sketch: Foreign academician of the Russian Academy of Engineering, second-class professor, doctoral supervisor. PhD, Institute of Biophysics, Chinese Academy of Sciences.

Foreign academician of the Russian Academy of Engineering, second-class professor, doctoral supervisor. PhD, Institute of Biophysics, Chinese Academy of Sciences. Hubei Province "Chutian Scholar" Distinguished Professor, Hubei Province "Hundred Talents Program" expert, Hubei Province outstanding contribution young and middle-aged experts, "Wuhan Yellow Crane Talents" industry leader, Donghu High-tech Zone "3551 Optics Valley Talent" Program, National Major Science and Technology Project "863" and national key basic research and development plan "973" project expert. He has been engaged in the research of the transcriptional regulation mechanism of cardiovascular disease and tumor pathophysiology in the National Institute of Health and Environmental effects, the Cardiovascular Institute of the University of North Carolina School of Medicine and other institutions. In 2000, he won the US NRC fellowship award; in 2003, he won the US EPA Science and Technology Progress Award. One of the founders of Lacus Biotechnology Inc in the United States, with rich experience in biotechnology research and industrialization. In 2006, he returned to China to devote himself to the research and development of tumor treatment technology, and presided over dozens of National Natural Science Foundation projects, "863", "973" projects and Hubei Science and Technology Plan Natural Science Fund. The main research areas include gene regulation and major human diseases, biological drug development, joint research and development of CAR-T immune cell therapy technology with Duke University and Stanford University, and more than 100 SCI papers published in international journals.